References
- Bjøal F. Review of treating mania with zuc-lopenthixol: looking for a therapeutic window. Nord Psykiatr Tidsskr 1990; 44: 383–6
- Licht R. W., Gouliaev G., Vestergaard P. Treatment of acute mania with lithium and clonazepam or zuclopenthixol and clonazepam [abstract]. Psycho-pharmacology 1992; 107: B7
- Aaes-Jønsen T. Specific high-performance liquid chromatographic method for estimation of the cis(Z)- and trans(E)-isomers of clopenthixol and N-dealkylated metabolite. J Chromatogr 1980; 183: 239–45
- Larsen N-E, Hansen L. B., Kundsen P. Quantitative determination of perphenazine and its dealkylated metabolite using high-performance liquid chromatography. J. Chromatogr 1985; 341: 818–24
- Bolvig Hansen L., Larsen N-E, Gulmann N. Dose response relationships of perphenazine in treatment of acute psychoses. Psychopharmacology 1982; 78: 112–5
- Haffner F. Perphenazine serum levels in patients on standard doses. Clinical pharmacology in psychiatry, S. G. Dahl, L. F. Gram. Springer-Verlag, Berlin 1989; 280–3
- Dahl S. G. Pharmacokinetics of antipsychotic drugs in man. Acta Psychiatr Scand 1990; 82(Suppl 358)37–40
- Dahl M-L, Ekqvist B., Widen J., Bertilsson L. Disposition of the neuroleptic zuclopenthixol cosegre-gates with the polymorphic hydroxylation of de-brisoquine in humans. Acta Psychiatr Scand 1991; 84: 99–100
- Dahl-Puustinen M. L., Liden A., Aim C., Nordin C., Bertilsson L. Disposition of perphenazine is related to polymorphic hydroxylation in human being. Clin Pharmacol Ther 1989; 46: 78–81
- Szukalski B., Lipska B., Welbel L., Nurowska K. Serum levels and clinical response in long-term pharmacotherapy with zuclopenthixol decanoate. Psychopharmacology 1986; 89: 428–31
- Jønsen A., Aaes-Jørgensen T., Gravem A., Am-Thor KF, Dencker S. J., Resell I. Zuclopenthixol decanoate in schizophrenia: serum levels and clinical state. Psychopharmacology 1985; 87: 364–7